Principal Financial Group Inc. Increases Stake in ICU Medical, Inc. (NASDAQ:ICUI)

Principal Financial Group Inc. grew its position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 24.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 126,937 shares of the medical instruments supplier's stock after purchasing an additional 25,031 shares during the quarter. Principal Financial Group Inc. owned approximately 0.52% of ICU Medical worth $23,130,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Motco acquired a new position in ICU Medical in the first quarter valued at $29,000. Innealta Capital LLC acquired a new position in ICU Medical in the 2nd quarter valued at about $32,000. Hexagon Capital Partners LLC raised its stake in ICU Medical by 162.7% during the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier's stock valued at $36,000 after acquiring an additional 122 shares during the last quarter. Allworth Financial LP lifted its position in ICU Medical by 100.0% during the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier's stock worth $36,000 after acquiring an additional 100 shares during the period. Finally, EntryPoint Capital LLC grew its stake in shares of ICU Medical by 731.5% in the 1st quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier's stock valued at $48,000 after purchasing an additional 395 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on ICUI shares. KeyCorp increased their price target on ICU Medical from $198.00 to $209.00 and gave the stock an "overweight" rating in a report on Wednesday. Raymond James raised their target price on shares of ICU Medical from $158.00 to $190.00 and gave the stock an "outperform" rating in a research note on Thursday, September 12th. Jefferies Financial Group began coverage on shares of ICU Medical in a research note on Monday, October 14th. They set a "hold" rating and a $183.00 price target on the stock. Needham & Company LLC reiterated a "hold" rating on shares of ICU Medical in a research report on Wednesday. Finally, StockNews.com cut ICU Medical from a "buy" rating to a "hold" rating in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $173.00.

Insider Activity at ICU Medical

In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the company's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the sale, the vice president now owns 13,107 shares of the company's stock, valued at $2,139,324.54. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, VP Daniel Woolson sold 2,502 shares of the business's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the transaction, the vice president now directly owns 13,107 shares of the company's stock, valued at $2,139,324.54. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the company's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total value of $2,141,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares in the company, valued at $18,665,666.78. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,502 shares of company stock valued at $8,445,976. Insiders own 6.70% of the company's stock.

ICU Medical Price Performance

Shares of NASDAQ:ICUI traded down $1.08 during trading on Thursday, hitting $173.73. 308,906 shares of the stock were exchanged, compared to its average volume of 275,044. The company has a market cap of $4.24 billion, a PE ratio of -38.25 and a beta of 0.66. The company has a current ratio of 2.41, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76. The company has a fifty day moving average price of $176.11 and a two-hundred day moving average price of $141.98. ICU Medical, Inc. has a 12-month low of $82.82 and a 12-month high of $196.26.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its earnings results on Tuesday, November 12th. The medical instruments supplier reported $1.23 EPS for the quarter, topping analysts' consensus estimates of $0.88 by $0.35. The company had revenue of $580.07 million for the quarter, compared to the consensus estimate of $574.77 million. ICU Medical had a positive return on equity of 5.04% and a negative net margin of 4.74%. On average, analysts forecast that ICU Medical, Inc. will post 3.81 EPS for the current year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.